TENX - テナックス・セラピュ―ティックス (Tenax Therapeutics Inc.)

TENXのニュース

   Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)  2021/10/06 12:30:00 Business Wire
Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for imatinib.
   Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)  2021/08/12 12:00:00 Business Wire
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces article in Journal of Cardiac Failure identifying novel mechanism of action in Phase 2 HELP Study
   Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)  2021/08/05 12:00:00 Business Wire
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.
   Tenax Therapeutics pulls in $10M two weeks after naming new CEO | WRAL TechWire  2021/07/22 17:36:07 WRAL TechWire
MORRISVILLE - Two weeks after naming a new CEO, the publicly-traded Tenax Therapeutics, Inc. (Nasdaq: TENX) has raised nearly $10 million from an undisclosed
   Traumatic Brain Injuries Treatment Market 2021 Industry Outlook, Comprehensive Insights and Forecast 2026 | Neuren Pharmaceuticals, TEVA Pharmaceutical Industries, Grace Laboratories, NeuroScience Pharmaceuticals, Tenax Therapeutics  2021/07/14 11:17:37 Tramways Monthly
Report Hive Research Market Reports has recently published a market research report titled, Traumatic Brain Injuries Treatment Market Size, Status and Forecast 2021-2026. Analysts have used primary and secondary research methodologies to determine the path of the market. The data includes historic and forecast values for a well-rounded understanding. It is a phenomenal compilation []
   Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)  2021/08/12 12:00:00 Business Wire
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces article in Journal of Cardiac Failure identifying novel mechanism of action in Phase 2 HELP Study
   Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)  2021/08/05 12:00:00 Business Wire
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.
   Tenax Therapeutics pulls in $10M two weeks after naming new CEO | WRAL TechWire  2021/07/22 17:36:07 WRAL TechWire
MORRISVILLE - Two weeks after naming a new CEO, the publicly-traded Tenax Therapeutics, Inc. (Nasdaq: TENX) has raised nearly $10 million from an undisclosed
   Traumatic Brain Injuries Treatment Market 2021 Industry Outlook, Comprehensive Insights and Forecast 2026 | Neuren Pharmaceuticals, TEVA Pharmaceutical Industries, Grace Laboratories, NeuroScience Pharmaceuticals, Tenax Therapeutics  2021/07/14 11:17:37 Tramways Monthly
Report Hive Research Market Reports has recently published a market research report titled, Traumatic Brain Injuries Treatment Market Size, Status and Forecast 2021-2026. Analysts have used primary and secondary research methodologies to determine the path of the market. The data includes historic and forecast values for a well-rounded understanding. It is a phenomenal compilation []
   Former Iqvia senior exec named CEO of Morrisville-based Tenax Therapeutics  2021/07/09 02:42:42 WRAL TechWire
(WRAL TechWire)

calendar